SBIR Phase II: Transcranial Dynamic Focused Ultrasound for the Non-Invasive Opening of the Blood-Brain Barrier (BBB)

SBIR 第二阶段：经颅动态聚焦超声非侵入性打开血脑屏障 (BBB)

• 批准号: 2111810
• 负责人: Bhaskar Ramamurthy
• 金额: $ 99.85万
• 依托单位: CORDANCE MEDICAL INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2111810&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Transcranial; Dynamic

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to enable new therapeutic strategies to treat brain diseases such a brain cancer. Treating brain diseases is challenging partly because of the existence of an anatomical structure called the blood-brain barrier. This barrier prevents the entry of almost all therapeutic molecules into the brain tissue from the blood. This has led to a devastating impact on the patients and society as a whole. As an example, for glioblastoma, the most common form of primary malignant brain tumors, the five-year survival rate is only 6.8%. Impact and commercial potential include increased treatment options where few or none are available and improved patient outcomes, all with a system that is patient-friendly and designed to cause minimal disruption to the existing treatment workflows. Additionally, the advancement of this project will provide a convenient tool for drug developers to study and develop new drugs without the need to develop a special carrier to transport drugs into the brain. This Small Business Innovation Research (SBIR) Phase II project involves designing and building a prototype version of a system that can deliver therapies to the brain in a non-invasive and non-intrusive manner. The performance of this system to accurately deliver to regions of interest within the brain will be measured and characterized in a test environment mimicking that of a human head. This project will advance a prototype for use in both clinical and research settings.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力是使新的治疗策略能够治疗此类脑癌。治疗脑部疾病的挑战部分是因为存在一种称为血脑屏障的解剖结构。该障碍可防止几乎所有治疗分子从血液中进入脑组织。这导致了对整个患者和社会的毁灭性影响。例如，对于胶质母细胞瘤，是原发性恶性脑肿瘤的最常见形式，五年生存率仅为6.8％。影响和商业潜力包括增加或无法获得的治疗选择，并且患者的结果改善，所有这些系统都具有患者友好的系统，并旨在使现有的治疗工作流程最小的干扰。此外，该项目的进步将为药物开发人员提供方便的工具研究和开发新药，而无需开发特殊的载体将药物运输到大脑中。这项小型企业创新研究（SBIR）第二阶段项目涉及设计和构建系统的原型版本，该系统可以以无创和非侵入性的方式为大脑提供疗法。该系统的性能准确地传递到大脑内感兴趣的区域，将在模仿人头的测试环境中进行测量和表征。该项目将推进用于临床和研究环境中的原型。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛的影响评估标准来评估的。